Vera Therapeutics
Vera Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of transformative immunological treatments for serious autoimmune and severe inflammatory diseases, prominently featuring its lead product candidate atacicept for the treatment of IgA nephropathy (Berg's disease). The company conducts advanced clinical trials evaluating targeted biological therapies designed to address the underlying immunological drivers of severe kidney and autoimmune disorders. Its core business operations encompass biopharmaceutical immunology research, clinical trial execution, biologic drug formulation, and commercial pharmaceutical strategy. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and institutional financing. Vera Therapeutics holds a leading market position in targeted immunology and nephrology therapeutics. The company is headquartered in Brisbane, California, United States, and its common stock trades on the Nasdaq Global Market.
4 of the funds FundTelligence covers report a position in Vera Therapeutics.
- Legal name
- Vera Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Vera Therapeutics
- Lannebo Global Småbolag — Lannebo · 1.61 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)